No Carolina / NY / Florida
Ph: 561.316.3330

FDA Clears CorNeat EverPatch, World’s First Non-degradable, Synthetic Tissue Substitute for Ophthalmic Surgery

Summation

  • It is composed of a non-woven, polymer matrix which integrates with surrounding tissue and is intended to reinforce the sclera and aid the physical reconstruction of the ocular surface.
  • The CorNeat EverPatch is poised to displace the use of donor and processed tissue, commonly utilized in ocular surgeries but posing the risk of disease transmission.
  • EverMatrix™ presents a significant business opportunity as it is the only synthetic non-degradable patch material in ocular surgery.

CorNeat Vision’s EverPatch, a synthetic tissue substitute, has been granted 510(k) clearance by the US Food & Drug Administration (FDA). The CorNeat EverPatch is the first synthetic, non-degradable tissue-integrating matrix for use in ophthalmic surgeries. It is composed of a non-woven, polymer matrix which integrates with surrounding tissue and is intended to reinforce the sclera and aid the physical reconstruction of the ocular surface. This groundbreaking synthetic tissue substitute is designed to address the critical needs of ocular surgeons, providing a sterile and non-degradable solution for patients worldwide.

The CorNeat EverPatch is poised to displace the use of donor and processed tissue, commonly utilized in ocular surgeries but posing the risk of disease transmission.

Dr. Gilad Litvin, CorNeat Vision’s Chief Medical Officer and Co-Founder stated: “The ideal graft material should be long-lasting, sterile, immunologically inactive, cosmetically acceptable, and readily available. The CorNeat EverPatch was designed with these goals in mind. Our novel ophthalmic patch is significantly thinner than processed patch tissue, provides better handling as it does not ‘cheesewire’ when sutured, and has holes that allow for accurate positioning and anchoring. These holes also facilitate direct conjunctival adhesion to the sclera thus supporting its bio-integration. Thus far, we have received extremely positive feedback from surgeons and are excited for U.S. surgeons to have this tool available.”

Almog Aley-Raz, CorNeat Vision’s CEO and VP R&D responded to the news: “We are extremely excited to introduce the CorNeat EverPatch to the U.S. market. It is the first device that leverages the EverMatrix™, our core tissue-integrating material platform technology, originally developed for our corneal prosthesis program. EverMatrix™ presents a significant business opportunity as it is the only synthetic non-degradable patch material in ocular surgery. This biocompatible material has the potential for wider use in soft tissue reinforcement, biomechanical integration of implants with surrounding tissue, fabrication of membranes, and concealment of implants and sensors. I cannot overemphasize the potential impact of this technology on human health. This recent FDA clearance of our first device for ophthalmic use advances us toward our ultimate goal of promoting human health and equality.”

The CorNeat EverPatch will be launched initially in leading ophthalmic centers in the U.S. in Q3 2023, expanding nationwide later in the year.

Other FDA News of Interest

Indica Labs Receives FDA Clearance for HALO AP Dx Digital Pathology Platform for Use with Hamamatsu Images Acquired with the NanoZoomer® S360MD Slide Scanner

Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the...

FDA Grants AI-Powered Notal Vision Home OCT “SCANLY” De Novo Marketing Authorization

“We are very excited to receive FDA authorization to market SCANLY Home OCT as the first-ever patient self-operated, home-use device that gives physicians remote access to high-resolution, cross-sectional retinal images and AI-based analytical biomarkers of their patients eyes between office visits,” said Kester Nahen, PhD, CEO of Notal Vision. “We look forward to supporting our referring physicians in navigating their wet AMD patients’ care.”

Atraverse Medical Receives FDA Clearance for HOTWIRE™ Left Heart Access Device, Oversubscribes Seed Round with $12.5M Invested

The HOTWIRE system, invented by Atraverse Medical Co-Founders Dr. Steven Mickelsen and Eric Sauter, introduces a paradigm shift in left-heart access.

By using this website you agree to accept Medical Device News Magazine Privacy Policy